Merck Financial Statements From 2010 to 2021

MRK -  USA Stock  

USD 81.66  0.51  0.63%

Merck financial statements provide useful quarterly and yearly information to potential Merck Company investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Merck financial statements helps investors assess Merck's valuation, profitability, and current liquidity needs.
There are currently one hundred sixteen fundamental ratios for Merck that can be evaluated and compared over time across peers in the industry. Please compare all of Merck last-minute fundamentals against the fundamentals between 2010 and 2021 to make sure the company is sustainable this year.
Merck Invested Capital is increasing as compared to previous years. The last year's value of Invested Capital was reported at 55.02 Billion. The current Invested Capital Average is estimated to increase to about 58.6 B, while Average Assets are projected to decrease to under 88.2 B.

Merck Financial Statements 

 
Refresh
Check Merck financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Merck main balance sheet or income statement drivers, such as Direct Expenses of 17.1 B, Consolidated Income of 7.1 B or Cost of Revenue of 14.7 B, as well as many exotic indicators such as Interest Coverage of 11.47, Long Term Debt to Equity of 1.08 or Calculated Tax Rate of 27.01. Merck financial statements analysis is a perfect complement when working with Merck Valuation or Volatility modules. It can also supplement various Merck Technical models. Additionally, see the analysis of Merck Correlation against competitors.

Merck Revenues

43.79 BillionShare

Merck Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets88.9 B91.6 B96.1 B
Decreasing
Slightly volatile
Cash and Equivalents8.4 B8.1 B9.7 B
Decreasing
Slightly volatile
Investments805.7 M785 M9.5 B
Decreasing
Stable
Investments Current913.5 M890.1 M2.8 B
Decreasing
Stable
Investments Non Current805.7 M785 M6.8 B
Decreasing
Stable
Property Plant and Equipment Net15.1 B17 B14.6 B
Decreasing
Stable
Inventory5.3 B5.6 B5.6 B
Decreasing
Slightly volatile
Tax Assets5.3 B5.5 B4.7 B
Increasing
Slightly volatile
Trade and Non Trade Receivables6.6 B6.8 B7.1 B
Decreasing
Slightly volatile
Trade and Non Trade Payables3.9 B4.3 B2.9 B
Increasing
Slightly volatile
Goodwill and Intangible Assets33.3 B33 B37.4 B
Decreasing
Slightly volatile
Total Liabilities66.2 B66.2 B55.2 B
Increasing
Slightly volatile
Shareholders Equity30.8 B25.3 B40.7 B
Decreasing
Slightly volatile
Accumulated Retained Earnings Deficit49.6 B47.4 B43.2 B
Increasing
Slightly volatile
Current Assets27.3 B27.8 B29.9 B
Decreasing
Slightly volatile
Assets Non Current61.6 B63.8 B66.2 B
Decreasing
Slightly volatile
Current Liabilities25.6 B27.3 B19.9 B
Increasing
Slightly volatile
Liabilities Non Current40.6 B38.9 B35.3 B
Increasing
Slightly volatile
Tax Liabilities2.7 B2.6 B7.1 B
Decreasing
Slightly volatile
Total Debt30.5 B31.8 B24.3 B
Increasing
Slightly volatile
Debt Current5.4 B6.4 B3.6 B
Increasing
Slightly volatile
Debt Non Current25.1 B25.4 B20.7 B
Increasing
Slightly volatile
Shareholders Equity USD30.8 B25.3 B40.7 B
Decreasing
Slightly volatile
Cash and Equivalents USD8.4 B8.1 B9.7 B
Decreasing
Slightly volatile
Total Debt USD30.5 B31.8 B24.3 B
Increasing
Slightly volatile
Accounts PayableB4.6 BB
Increasing
Slightly volatile
Receivables8.3 B7.9 B7.3 B
Increasing
Very volatile
Inventories6.6 B6.3 B5.8 B
Decreasing
Very volatile

Merck Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Revenues43.8 B48 B44 B
Decreasing
Stable
Cost of Revenue14.7 B15.5 B15.4 B
Decreasing
Slightly volatile
Selling General and Administrative Expense10.3 B10.5 B11.3 B
Decreasing
Slightly volatile
Research and Development Expense12.6 B13.6 B9.6 B
Increasing
Slightly volatile
Operating Expenses22 B24.6 B21.6 B
Decreasing
Stable
Income Tax Expense2.1 B1.7 BB
Increasing
Stable
Consolidated Income7.1 B7.1 B5.9 B
Increasing
Stable
Net Income to Non Controlling Interests15.4 M15 M41.5 M
Decreasing
Slightly volatile
Net Income7.1 B7.1 B5.9 B
Increasing
Slightly volatile
Net Income Common Stock7.1 B7.1 B5.9 B
Increasing
Slightly volatile
Weighted Average Shares2.5 B2.5 B2.8 B
Decreasing
Slightly volatile
Weighted Average Shares DilutedB2.5 B2.9 B
Decreasing
Slightly volatile
Earning Before Interest and Taxes EBIT9.1 B8.8 B7.9 B
Increasing
Stable
Revenues USD43.8 B48 B44 B
Decreasing
Stable
Net Income Common Stock USD7.1 B7.1 B5.9 B
Increasing
Slightly volatile
Earning Before Interest and Taxes USD9.1 B8.8 B7.9 B
Increasing
Stable
Gross Profit33.6 B32.5 B28.9 B
Increasing
Slightly volatile
Operating Income8.2 B7.9 B7.1 B
Increasing
Slightly volatile
Direct Expenses17.1 B15.5 B15.6 B
Decreasing
Slightly volatile

Merck Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Net Cash Flow Business Acquisitions and Disposals(7.8 B)(7.6 B)(1.6 B)
Decreasing
Slightly volatile
Net Cash Flow Investment Acquisitions and Disposals2.9 B2.7 B497.1 M
Increasing
Slightly volatile
Issuance Repayment of Debt Securities 5.4 BB1.5 B
Increasing
Stable
Net Cash Flow from Investing(9.7 B)(9.4 B)(3.3 B)
Decreasing
Stable
Net Cash Flow from Operations9.9 B10.3 B10.6 B
Decreasing
Very volatile
Effect of Exchange Rate Changes on Cash 273 M253 M(152.3 M)
Increasing
Slightly volatile
Net Cash Flow or Change in Cash and Cash Equivalents(1.8 B)(1.8 B)(246.8 M)
Decreasing
Stable
Share Based Compensation456.2 M475 M364.5 M
Increasing
Stable
Depreciation Amortization and Accretion4.3 B3.6 B5.7 B
Decreasing
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Earnings per Basic Share2.672.792.1232
Increasing
Slightly volatile
Earnings per Diluted Share2.652.782.1036
Increasing
Slightly volatile
Earnings per Basic Share USD2.672.792.1232
Increasing
Slightly volatile
Dividends per Basic Common Share2.392.481.9116
Increasing
Slightly volatile
Return on Average Equity0.230.2610.1568
Increasing
Slightly volatile
Return on Average Assets0.07640.0790.0615
Increasing
Slightly volatile
Return on Invested Capital0.170.170.1457
Increasing
Slightly volatile
Gross Margin0.740.6770.6549
Increasing
Slightly volatile
Profit Margin0.150.1470.1323
Increasing
Stable
EBITDA Margin0.310.2580.3098
Increasing
Very volatile
Return on Sales0.20.1830.179
Increasing
Stable
Asset Turnover0.550.5380.4605
Increasing
Slightly volatile
Payout Ratio1.060.8891.3838
Decreasing
Slightly volatile
Enterprise Value over EBITDA17.518.41313.8144
Increasing
Slightly volatile
Enterprise Value over EBIT25.8626.028.6548
Decreasing
Stable
Price to Earnings Ratio32.2429.31939.2889
Decreasing
Stable
Sales per Share19.0918.9716.0125
Increasing
Slightly volatile
Price to Sales Ratio4.394.3123.7139
Increasing
Slightly volatile
Price to Book Value6.898.1754.6689
Increasing
Slightly volatile
Debt to Equity Ratio2.222.6141.5167
Increasing
Slightly volatile
Dividend Yield0.02990.030.0333
Decreasing
Slightly volatile
Current Ratio1.211.0161.5713
Decreasing
Slightly volatile
Free Cash Flow per Share2.432.2012.9615
Decreasing
Stable
Book Value per Share11.4210.00714.3399
Decreasing
Slightly volatile
Tangible Assets Book Value per Share24.3723.16421.322
Increasing
Slightly volatile
Total Assets Per Share39.0536.197634.9111
Increasing
Stable
Cash Flow Per Share3.734.05223.7973
Increasing
Stable
Return on Investment12.2914.456711.222
Increasing
Slightly volatile
Operating Margin15.416.470815.9295
Increasing
Slightly volatile
Calculated Tax Rate27.0119.440328.8038
Decreasing
Stable
Receivables Turnover6.046.54366.1508
Increasing
Very volatile
Inventory Turnover2.882.52032.6925
Decreasing
Stable
PPandE Turnover2.82.89743.0107
Increasing
Slightly volatile
Cash and Equivalents Turnover4.835.39664.7347
Increasing
Slightly volatile
Accounts Payable Turnover15.7111.488916.6063
Decreasing
Slightly volatile
Accrued Expenses Turnover34.4329.354732.9158
Decreasing
Slightly volatile
Interest Coverage11.4710.239614.2001
Increasing
Stable
Long Term Debt to Equity1.081.00170.5948
Increasing
Slightly volatile
Quick Ratio0.60.5821.027
Decreasing
Slightly volatile
Net Current Assets as percentage of Total Assets0.490.47719.9124
Decreasing
Slightly volatile
Revenue to Assets0.470.5240.4589
Increasing
Slightly volatile

Merck Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Earnings before Tax9.1 B8.8 B7.9 B
Increasing
Stable
Earnings Before Interest Taxes and Depreciation Amortization EBITDA12.2 B12.4 B13.5 B
Decreasing
Very volatile
Earnings Before Interest Taxes and Depreciation Amortization USD12.2 B12.4 B13.5 B
Decreasing
Very volatile
Market Capitalization201.5 B207 B163.4 B
Increasing
Slightly volatile
Enterprise Value220.9 B228.3 B177.8 B
Increasing
Slightly volatile
Invested Capital60 B55 B54.1 B
Increasing
Stable
Average Equity32.4 B27.1 B42.3 B
Decreasing
Slightly volatile
Average Assets88.2 B89.2 B97.2 B
Decreasing
Slightly volatile
Invested Capital Average58.6 B51.6 B54.6 B
Increasing
Stable
Tangible Asset Value55.7 B58.6 B58.7 B
Decreasing
Slightly volatile
Free Cash Flow6.5 B5.6 B8.3 B
Decreasing
Slightly volatile
Working Capital448.5 M437 M9.9 B
Decreasing
Slightly volatile
Revenue Per Employee587.9 K646.8 K587.7 K
Increasing
Slightly volatile
Net Income Per Employee83.3 K95.2 K79.1 K
Increasing
Slightly volatile

Merck Fundamental Market Drivers

Forward Price Earnings12.58
Short Percent Of Float0.88%
Average Daily Volume Last 10 Day12.24M
Shares Short Prior Month22.07M
Average Daily Volume In Three Month13.37M
Date Short Interest15th of July 2021
Fifty Day Average76.50
Two Hundred Day Average75.77

Merck Upcoming Events

Upcoming Quarterly Report28th of October 2021
Next Earnings Report3rd of February 2022
Next Fiscal Quarter End30th of September 2021
Next Fiscal Year End3rd of February 2022
Last Quarter Report30th of June 2021
Last Earning Announcement30th of September 2020

About Merck Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Merck income statement, its balance sheet, and the statement of cash flows. Merck investors use historical funamental indicators, such as Merck's revenue or net income, to determine how well the company is positioned to perform in the future. Although Merck investors may use each financial statement separately, they are all related. The changes in Merck's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Merck's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Merck Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Merck. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2021
Cost of Revenue15.5 B14.7 B
Revenues48 B43.8 B
Revenue to Assets 0.52  0.47 
Revenue Per Employee646.8 K587.9 K
Merck Co., Inc. operates as a healthcare company worldwide. Merck Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey. Merck operates under Drug ManufacturersGeneral classification in the United States and is traded on New York Stock Exchange. It employs 73000 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Merck without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Stock Screener Now

   

Stock Screener

Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
All  Next Launch Module

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Merck Company using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Additionally, see the analysis of Merck Correlation against competitors. Note that the Merck Company information on this page should be used as a complementary analysis to other Merck's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.

Complementary Tools for Merck Stock analysis

When running Merck Company price analysis, check to measure Merck's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Merck is operating at the current time. Most of Merck's value examination focuses on studying past and present price action to predict the probability of Merck's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Merck's price. Additionally, you may evaluate how the addition of Merck to your portfolios can decrease your overall portfolio volatility.
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Go
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Go
Money Managers
Screen money managers from public funds and ETFs managed around the world
Go
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Go
Is Merck's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Merck. If investors know Merck will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Merck listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Merck Company is measured differently than its book value, which is the value of Merck that is recorded on the company's balance sheet. Investors also form their own opinion of Merck's value that differs from its market value or its book value, called intrinsic value, which is Merck's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Merck's market value can be influenced by many factors that don't directly affect Merck's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Merck's value and its price as these two are different measures arrived at by different means. Investors typically determine Merck value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Merck's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.